Hepatitis Monthly

Published by: Kowsar

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

Ehsan Aminizadeh 1 , 2 , * , Seyed Moayyed Alavian 3 , Ali Akbari Sari 2 , Nasser Ebrahimi Daryani 1 and Bita Behnava 3
Authors Information
1 Department of Gastroenterology, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
3 Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: March 2016, 16 (3); e28537
  • Published Online: March 6, 2016
  • Article Type: Review Article
  • Received: September 5, 2015
  • Revised: January 15, 2016
  • Accepted: January 15, 2016
  • DOI: 10.5812/hepatmon.28537

To Cite: Aminizadeh E, Alavian S M, Akbari Sari A, Ebrahimi Daryani N, Behnava B. et al. Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials, Hepat Mon. 2016 ;16(3):e28537. doi: 10.5812/hepatmon.28537.

Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9): 558-67[DOI][PubMed]
  • 2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 3. Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997; 26(3): 521-6[DOI][PubMed]
  • 4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013; 10(9): 553-62[DOI][PubMed]
  • 5. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006; 9(4): 319-23[PubMed]
  • 6. Wasley A, Grytdal S, Gallagher K, Centers for Disease C. Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ. 2008; 57(2): 1-24[PubMed]
  • 7. Angelucci E, Pilo F. Treatment of hepatitis C in patients with thalassemia. Haematologica. 2008; 93(8): 1121-3[DOI][PubMed]
  • 8. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[DOI][PubMed]
  • 9. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001; 33(2): 433-8[DOI][PubMed]
  • 10. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997; 26(2): 473-7[DOI][PubMed]
  • 11. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005; 130(4): 644-6[DOI][PubMed]
  • 12. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002; 117(3): 755-8[PubMed]
  • 13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343[DOI][PubMed]
  • 14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539-58[DOI][PubMed]
  • 15. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987; 6(3): 341-50[PubMed]
  • 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88[PubMed]
  • 17. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007; 26(1): 53-77[DOI][PubMed]
  • 18. Behnava B, Keshvari M, Miri SM, Elizee PK, Alavian SM. Reactivation of brucellosis during pegylated interferon-alpha therapy in a thalassemic patient with chronic hepatitis C. Exp Clin Hepatol. 2011; 7(1–2)-9
  • 19. Sherker AH, Senosier M, Kermack D. Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin. Hepatology. 2003; 37(1): 223[DOI][PubMed]
  • 20. Hamidah A, Thambidorai CR, Jamal R. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based. Med J Malaysia. 2005; 60(4): 517-9[PubMed]
  • 21. Sharara AI, Aoun E, Koussa S, Inati A, Taher A. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. J Gastroenterol Hepatol. 2006; 21(7): 1221[DOI][PubMed]
  • 22. Pagliano P, Costantini S, Gradoni L, Faella FS, Spasiano A, Mascarella G, et al. Distinguishing visceral leishmaniasis from intolerance to pegylated interferon-alpha in a thalassemic splenectomized patient treated for chronic hepatitis C. Am J Trop Med Hyg. 2008; 79(1): 9-11[PubMed]
  • 23. Mobini N. Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection; A rare complication. Caspian J Intern Med. 2010; 1(3): 111-4
  • 24. Hamidah A, Yong JF, Zulkifli HI, Jamal R. Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia. Med J Malaysia. 2002; 57(3): 353-6[PubMed]
  • 25. Uslu N, Baysoy G, Demir H, Temizel IN, Yuce A. Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection. J Clin Virol. 2010; 48(1): 66-8[DOI][PubMed]
  • 26. Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Baronciani D, et al. Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant. 1997; 20(9): 767-72[DOI][PubMed]
  • 27. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol. 1999; 14(9): 893-8[PubMed]
  • 28. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010; 17(4): 236-44[DOI][PubMed]
  • 29. Bourliere M, Halfon P, Portal I. [Treatment of chronic hepatitis C in special groups]. Gastroenterol Clin Biol. 2002; 26 Spec No 2-47[PubMed]
  • 30. Uysal Z, Cin S, Arcasoy A, Akar N. Interferon treatment of hepatitis B and C in beta-thalassemia. Pediatr Hematol Oncol. 1995; 12(1): 87-9[PubMed]
  • 31. Russo-Mancuso G, Di Gregorio F, Passero E, Sciotto A, Mazzarino MC, Malaponte G, et al. Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study. Br J Haematol. 1995; 89(2): 291-8[PubMed]
  • 32. Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, et al. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J. 1997; 16(11): 1049-53[PubMed]
  • 33. Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009; 21(7): 726-9[DOI][PubMed]
  • 34. Paschos P, Vlachaki E, Pasvanti C, Sinakos E, Kalpaka A, Klonizakis P, et al. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience. Acta Haematol. 2011; 126(4): 231-3[DOI][PubMed]
  • 35. Leonardi S, Avola E, Delfa WL, Di Gregorio F, Musumeci S. Interferon-α Therapy in Thalassemic Patients with Chronic Non-A, Non-B Hepatitis. Ann NY Acad Sci. 1990; 612(1): 553-5[DOI]
  • 36. Report of the first patients with thalassemia in the United States treated with combination therapy for hepatitis C virus. Blood : 38B
  • 37. Eleftheriou A, Christou S, Skordos G, Pavlides N. Factors predicting progression and response to treatment of HCV infection in thalassaemia major patients. Blood. 1999; 94(10): 31B
  • 38. Harmatz P, Olivieri NF, Vichinsky E, Kwiatkowski J, Giardina P, Shah F, et al. Early Hepatitis C Viral Response (EVR) to Peginterferon Alfa 2a and Ribavirin in Patients with β Thalassemia. ASH Ann Meet Abstr. 2004; 104(11): 3624
  • 39. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008; 93(8): 1247-51[DOI][PubMed]
  • 40. Inati A, Sharara AI, Ghorra S, Aoun E, Taha M, Koussa S, et al. Study on hepatitis C treatment using ribavirin and pegylated interferon in thalassemia patients (SCRIPT): One year report. ASH Ann Meet Abstr. 2004; 104(11): 3768
  • 41. Di Marco V, Lo Iacono O, Capra M, Grutta S, Ciaccio C, Gerardi C, et al. Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia. Gut. 1993; 34(2 Suppl)-3[PubMed]
  • 42. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br J Haematol. 1993; 83(3): 491-7[PubMed]
  • 43. Di Marco V, Lo Iacono O, Capra M, Grutta S, Ciaccio C, Gerardi C, et al. alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Haematologica. 1992; 77(6): 502-6[PubMed]
  • 44. Wonke B, Donohue SM, Hoffbrand AV, Scheuer PJ, Brown D, Dusheiko G. Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM). Bone Marrow Transplant. 1993; 12 Suppl 1: 24-5[PubMed]
  • 45. Malaponte G, Passero E, Leonardi S, Monte V, Lauria C, Mazzarino C, et al. Effect of alpha-interferon on natural killer cell activity and lymphocyte subsets in thalassemia patients with chronic hepatitis C. Acta Haematol. 1997; 98(2): 83-8[PubMed]
  • 46. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood. 1997; 90(6): 2207-12[PubMed]
  • 47. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol. 1997; 98(4): 850-5[PubMed]
  • 48. Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 1999; 18(10): 709-15[PubMed]
  • 49. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol. 2002; 97(4): 982-7[DOI][PubMed]
  • 50. Syriopoulou V, Daikos GL, Kostaridou SL, Manolaki N, Nakopoulou L, Kattamis A, et al. Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica. 2005; 90(1): 129-31[PubMed]
  • 51. Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother. 2005; 17(6): 651-5[DOI][PubMed]
  • 52. Chen AC, Peng CT, Wu SF, Wu KH, Chiang IP, Tsai CH. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia. Hemoglobin. 2006; 30(2): 209-14[DOI][PubMed]
  • 53. Saffar MJ, Saffar H, Khalilian AR, Naqshvar F. Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-thalassaemia major. East Mediterr Health J. 2009; 15(4): 785-91[PubMed]
  • 54. Ricchi P, Ammirabile M, Costantini S, Cinque P, Lanza AG, Spasiano A, et al. The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. Expert Opin Drug Saf. 2010; 9(6): 875-81[DOI][PubMed]
  • 55. Ricchi P, Lanza AG, Ammirabile M, Costantini S, Cinque P, Spasiano A, et al. Hepatitis C virus distribution and clearance following interferon-monotherapy among thalassaemia major and intermedia patients. Br J Haematol. 2011; 155(4): 524-7[DOI][PubMed]
  • 56. Jafroodi M, Asadi R, Heydarzadeh A, Besharati S. Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin. Int J Gen Med. 2011; 4: 529-33[DOI][PubMed]
  • 57. Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica. 2012; 97(5): 679-86[DOI][PubMed]
  • 58. Triantos C, Kourakli A, Kalafateli M, Giannakopoulou D, Koukias N, Thomopoulos K, et al. Hepatitis C in patients with beta-thalassemia major. A single-centre experience. Ann Hematol. 2013; 92(6): 739-46[DOI][PubMed]
  • 59. Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013; 90(6): 501-7[DOI][PubMed]
  • 60. Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E, et al. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit. Ann Hepatol. 2013; 12(4): 532-8[PubMed]
  • 61. Wonke B, Telfer P, Garson JA, Whitby K, Grant P, Rowntree C, et al. Alpha-interferon alone and in combination with ribavirin for hepatitis C infection in multiply tranfused patients with thalassemia major-the UK experience. Bone Marrow Transplant-Basingstoke-. 1997; 19: 163-5
  • 62. Diamantis I, Vafiadis I, Voskaridou E, Dellatetsima J, Jaggi N, Gyr K, et al. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur J Gastroenterol Hepatol. 1998; 10(1): 75-9[PubMed]
  • 63. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Matsouka P, Spiliopoulou II, Barbatis C. Adult beta-thalassemic patients with chronic hepatitis C: long-term efficacy of alpha-IFN treatment. Eur J Intern Med. 2000; 11(3): 161-4[PubMed]
  • 64. Mirmomen S, Ebrahimi Daryani N, Malekzadeh R, Zali MR, Haghpanah B, Poursamimi P. The efficacy and safety of peginterferon alpha-2a (PEGASYS) monotherapy in the treatment of chronic hepatitis C infected subjects with transfusion dependent thalassemia. Hepat Mon. 2004; 4(7): 65-70
  • 65. Mirmomen S, Ghofrani H, Forootan Pishbuary H, Ebrahimi Daryani N, Jafar Farahvash M, Sharifian RA, et al. Safety and efficacy of interferon alfa for the treatment of chronic hepatitis C infected subjects with transfusion dependent thalassemia in Iran. Med J Islamic Repub Iran (MJIRI). 2003; 17(2): 87-95
  • 66. Pizzarelli G, Di Gregorio F, Romeo MA, Carboni F, Gallisai D, Solinas A, et al. Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. BioDrugs. 1999; 12(1): 55-63[PubMed]
  • 67. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012; 12(6): 372-81[DOI][PubMed]
  • 68. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr. 1994; 125(1): 123-8[PubMed]
  • 69. Sood A, Sobti P, Midha V, Singla D, Kaur A, Kaushal S, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol. 2010; 29(2): 62-5[DOI][PubMed]
  • 70. Kalantari H, Rad N. Efficacy of interferon alpha-2b with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection: A randomized, double blind, controlled, parallel group trial. J Res Med Sci. 2010; 15(6): 310-6[PubMed]
  • 71. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 72. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 73. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006; 131(4): 1040-8[DOI][PubMed]
  • 74. Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir Ther. 2008; 13 Suppl 1: 23-30[PubMed]
  • 75. Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, et al. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology. 2007; 132(3): 921-30[DOI][PubMed]
  • 76. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol. 2007; 81(14): 7732-41[DOI][PubMed]
  • 77. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008; 47(1): 306-20[DOI][PubMed]
  • 78. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, et al. Gene expression and hepatitis C virus infection. Gut. 2009; 58(6): 846-58[DOI][PubMed]
  • 79. Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology. 2010; 139(1): 154-620000[DOI][PubMed]
  • 80. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology. 2011; 53(1): 32-41[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader